Folia Medica Indonesiana, 2022 Hightlight: • The effect of orlistat on glycemic control and weight loss in overweight or obese type 2 diabetes mellitus patients was determined • HbA1c and FPG level in overweight and obese type 2 diabetes mellitus patient can improved by orlistat as
Abu Rizal Dwikatmono Johan +6 more
doaj +3 more sources
36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report [PDF]
Nutrition Journal, 2006 Background Orlistat is an anti-obesity drug licensed in the United Kingdom for 7 years. We present a case of a patient who developed pancreatitis four days after commencing orlistat.
Thomas Matthew, Napier Sarah
doaj +2 more sources
High sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat) in vitro. [PDF]
PLoS ONE, 2013 Giardiasis, a gastrointestinal disease caused by Giardia duodenalis, is currently treated mainly with nitroimidazoles, primarily metronidazole (MTZ).
Juliane Hahn +6 more
doaj +3 more sources
Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial [PDF]
Lipids in Health and DiseaseBackground Weight gain and metabolic disorders are commonly induced by antipsychotics. Orlistat is a lipase inhibitor used for weight control. The effect of orlistat on weight gain and metabolic disturbances in people (especially women) treated with ...
Peng Xie +9 more
doaj +2 more sources
Impact of Orlistat-Induced Weight Loss on Diastolic Function and Heart Rate Variability in Severely Obese Subjects with Diabetes [PDF]
Journal of Obesity, 2011 Objective. Determine the impact of Orlistat-induced weight loss on metabolic profile and cardiovascular function in severely obese patients with type 2 diabetes. Methods.
Julie Martin +7 more
doaj +2 more sources
Effects of orlistat on APRI and FIB-4 scores in patients with obesity: a retrospective observational study. [PDF]
BMC Endocr DisordDurantas H +6 more
europepmc +2 more sources
Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis. [PDF]
BJGP OpenGhosal S, Heron N, Mason K, Jordan K.
europepmc +3 more sources
Myelopoietic efficacy of orlistat in murine hosts bearing T cell lymphoma: implication in macrophage differentiation and activation. [PDF]
PLoS ONE, 2013 Orlistat, an inhibitor of fatty acid synthase (FASN), acts as an antitumor agent by blocking de novo fatty acid synthesis of tumor cells. Although, myelopoiesis also depends on de novo fatty acid synthesis, the effect of orlistat on differentiation of ...
Shiva Kant +2 more
doaj +1 more source
Evaluating the Effect of Orlistat Administration on Depressive Behavior in Mice Following Inducing Depression by Water Avoidance Stress Model [PDF]
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2023 Introduction: The weight-loss drugs can induce depression. Orlistat is one of the common weight-loss drugs, but preclinical studies about its effect on mood have not been performed.
Nazanin Behrooz, Azadeh Mesripour
doaj
Nephrotoxicity associated with Orlistat in normal and obese female rats [PDF]
Journal of Bioscience and Applied Research, 2018 Obesity is a global health concern associated with high morbidity and mortality. Therapeutic strategies include synthetic drugs and surgery, which may entail high costs and serious complications. Orlistat is a pancreatic lipase inhibitor licensed for the
Ehab Tousson +3 more
doaj +1 more source